Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Eagle Pharmaceuticals Inc

EGRX
Current price
0.65 USD -0.27 USD (-29.35%)
Last closed 1.88 EUR
ISIN unknown
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange F
Capitalization 22 971 458 EUR
Yield for 12 month -86.14 %
1Y
3Y
5Y
10Y
15Y
EGRX
21.11.2021 - 28.11.2021

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Address: 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

44.79 EUR

P/E ratio

2.2564

Dividend Yield

Current Year

+292 373 505 EUR

Last Year

+158 414 154 EUR

Current Quarter

+59 697 349 EUR

Last Quarter

+61 229 352 EUR

Current Year

+204 704 855 EUR

Last Year

+119 463 033 EUR

Current Quarter

+44 129 829 EUR

Last Quarter

+45 253 667 EUR

Key Figures EGRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 62 777 993 EUR
Operating Margin TTM 15.94 %
PE Ratio 2.2564
Return On Assets TTM 6.63 %
PEG Ratio
Return On Equity TTM 4.88 %
Wall Street Target Price 44.79 EUR
Revenue TTM 259 414 624 EUR
Book Value 19.39 EUR
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -12.8 %
Dividend Yield
Gross Profit TTM 223 278 014 EUR
Earnings per share 0.79 EUR
Diluted Eps TTM 0.79 EUR
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY -87.1 %
Profit Margin 4.64 %

Dividend Analytics EGRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History EGRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation EGRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 2.2564
Forward PE 11.0988
Enterprise Value Revenue 0.2625
Price Sales TTM 0.0886
Enterprise Value EBITDA 1.2097
Price Book MRQ 0.0989

Financials EGRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators EGRX

For 52 weeks

1.77 EUR 13.19 EUR
50 Day MA 3.52 EUR
Shares Short Prior Month
200 Day MA 4.31 EUR
Short Ratio
Shares Short
Short Percent